MOHAMMAD AZAB - 19 Dec 2023 Form 4 Insider Report for Xenon Pharmaceuticals Inc. (XENE)

Role: Director
Signature: /s/ Sherry Aulin, Attorney-in-fact
Issuer symbol: XENE
Transactions as of: 19 Dec 2023
Net transactions value: +$42,552
Form type: 4
Filing time: 20 Dec 2023, 17:04:23 UTC
Previous filing: 23 Jun 2023
Next filing: 11 Jan 2024
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	XENE	Common Shares	Options Exercise	$8,107	+823	+1.2%	$9.85	70,728	19 Dec 2023	Direct	F1, F2
transaction	XENE	Common Shares	Options Exercise	$34,445	+3,497	+4.9%	$9.85	74,225	19 Dec 2023	Direct	F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	XENE	Stock Option (Right to Buy)	Options Exercise	$0	-823	-100%	$0.000000^*	0	19 Dec 2023	Common Shares	823	$9.85	Direct	F2
transaction	XENE	Stock Option (Right to Buy)	Options Exercise	$0	-3,497	-100%	$0.000000^*	0	19 Dec 2023	Common Shares	3,497	$9.85	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The common shares issued as a result of the exercise are subject to the terms of a Lock-Up Agreement executed by the Reporting Person in favor of the underwriters of the Company's follow-on public offering in November 2023.
F2	The exercise price was converted to U.S. dollars from $10.78 CAD using the closing rate of exchange on the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the date of exercise.